Do You Need TMG With NMN? What the Evidence Shows

The TMG-With-NMN Claim: Where It Comes From

Across the NMN supplement market, a recurring marketing claim goes roughly like this: "NMN raises NAD+. As NAD+ is used, it produces nicotinamide (NAM) as a byproduct. NAM must be cleared from the body by methylation, which consumes SAM (S-adenosylmethionine), your body's methyl donor. This depletes your methyl pool, potentially impairing DNA methylation, neurotransmitter synthesis, and other critical methylation processes. Therefore, you need TMG to replenish your methyl groups."

This argument contains a real biochemical mechanism at its core. The NNMT enzyme does methylate NAM to form N-methylnicotinamide (MeNAM) for urinary excretion, consuming SAM in the process. High-dose nicotinamide supplementation does stress the methyl pool in clinical conditions. David Sinclair has publicly mentioned taking TMG as a precaution when using NAD+ precursors. These facts are real.

The problem is the logical leap from "NAM methylation uses SAM" to "NMN supplementation meaningfully depletes your methyl pool." That leap requires assuming that NMN supplementation produces enough NAM to create significant methyl demand. Human clinical trial data directly contradicts this assumption.

The Key Distinction: NAM vs NMN in the Methylation Pathway

To understand why NMN does not carry the same methyl risk as NAM, the metabolic pathways need to be distinguished clearly.

How NAM creates methyl demand: When you supplement with plain nicotinamide (NAM), you are directly delivering the molecule that NNMT uses as its substrate for methylation-dependent excretion. Large supplemental doses of NAM overwhelm the recycling capacity of the NAMPT salvage pathway, resulting in excess NAM being routed to NNMT for methylation and excretion. Each molecule of NAM cleared this way consumes one SAM. At the high doses used in supplement form (500mg to several grams), this creates a substantial and measurable SAM demand.

How NMN reaches NAD+ by a different route: NMN enters the NAD+ biosynthetic pathway as the immediate precursor to NAD+, converted by NMNAT enzymes in a single step. It bypasses the NAM-to-NMN NAMPT step entirely. The NAM that eventually appears as a downstream catabolism product of NMN-derived NAD+ consumption is generated in physiologically regulated amounts determined by how much NAD+ your cells are actually consuming through Sirtuin, PARP, and CD38 activity. This is a fundamentally different flux than directly supplementing NAM at high doses.

The distinction is not subtle. NMN and NAM are different molecules that enter the NAD+ pathway at different steps and create different methylation burdens. Arguing that NMN supplementation depletes methyl groups because "NAD+ catabolism produces NAM" is like arguing that running depletes your electrolytes to dangerous levels because intense exercise increases sweat output. The mechanism is real; the magnitude at typical usage levels is not clinically significant.

The Human Evidence: What NMN Actually Does to Homocysteine

The Christen 2026 finding directly addressed the methyl depletion question with the most rigorous human experimental design possible: a randomised controlled trial measuring the established biomarker for methyl demand across three NAD+ precursors simultaneously. The result was not a marginal or ambiguous difference. NAM produced more than an eightfold homocysteine increase; NMN produced none detectable above placebo. This is not a subtle distinction.

This data is consistent with all existing NMN clinical trial safety data. Studies by Igarashi and colleagues (Keio University, 2022), Yi and Maier and colleagues (2023), and Fukamizu and colleagues (2022) involving hundreds of participants at doses from 250mg to 1,250mg per day all reported that NMN supplementation was well-tolerated with no adverse laboratory findings, including no methylation-related adverse effects, over trial periods of up to 12 weeks.

Why the TMG Claim Persists Despite the Evidence

Understanding why the methyl depletion narrative remains so persistent in NMN marketing requires looking at who repeats it and what incentives are at play.

The mechanism is technically correct, which makes it sound credible. "NAD+ consumption produces NAM; NAM is cleared by methylation; methylation uses SAM." Each sentence is true. The error is in the magnitude assumption: that the NAM produced downstream of NMN-derived NAD+ cycling creates a clinically significant SAM demand. Before the Christen 2026 trial, this could be reasonably described as a theoretical concern worth taking precautions against. After a direct human RCT measuring homocysteine under NMN supplementation and finding no elevation while finding massive elevation under NAM, describing TMG as "necessary" with NMN is an overclaim the evidence does not support.

Several factors explain why brands continue to push this narrative: selling TMG alongside NMN is an easy upsell to existing customers; the mechanism sounds scientific enough to generate anxiety; and David Sinclair's public comments about taking TMG as a personal precaution are amplified without the context that this was his individual precautionary choice, not a clinical recommendation derived from evidence of actual depletion.

When TMG Might Be Worth Considering

Intellectual honesty requires acknowledging that there are specific situations where TMG supplementation alongside NMN may be a reasonable individual decision, even if it is not required for most people.

Very high NMN doses above 1g per day. The Christen 2026 study used 1,000mg NMN and found no homocysteine elevation, which is reassuring for most users. At very high doses such as 2g or more, the downstream NAM catabolism load is proportionally higher and the margin of safety narrows. There are no human RCT data at these extreme doses measuring methylation markers. Caution is reasonable at the higher end of the dose range.

MTHFR gene variants. People with homozygous MTHFR C677T variants have reduced activity of the enzyme that produces 5-methyltetrahydrofolate, which is needed for one of the two main homocysteine remethylation routes. A 2023 study found that NR supplementation did not impair methylation even in people with MTHFR variants, but those individuals already have a compromised methylation capacity that could make any additional methyl demand more consequential. Adding TMG is a reasonable additional precaution for people who know they carry this variant.

Pre-existing elevated homocysteine. Anyone with already elevated plasma homocysteine has a baseline methylation challenge. TMG has established clinical evidence for homocysteine reduction independent of any NMN interaction, and for these individuals its benefits are real regardless of whether NMN is being taken.

Very low dietary methyl donors. Someone eating a severely methyl-depleted diet (very low animal protein, choline, or folate) may have reduced methylation reserve. For most people eating a varied diet, methyl donors from food are substantial and dwarf any increment from NMN catabolism.

What TMG Actually Is and Its Independent Evidence

TMG (trimethylglycine, also known as betaine anhydrous) is a naturally occurring compound found in beets, spinach, quinoa, and wheat bran. The body also produces it via the oxidation of choline. Each TMG molecule carries three methyl groups and donates one to homocysteine in the BHMT reaction, converting homocysteine back to methionine which regenerates SAM. This is an alternative methylation route that complements the folate-B12 dependent pathway.

TMG has its own clinical evidence base that is independent of NMN. Clinical trials have shown that 6g betaine per day lowers plasma homocysteine in healthy adults. Betaine at 2.5g per day has been studied in sports nutrition for improving power output and exercise performance through osmolyte effects on cellular hydration. Betaine is also used clinically for homocystinuria, a metabolic disorder characterised by very high homocysteine.

None of this evidence argues for or against TMG in the context of NMN supplementation. It establishes that TMG has genuine independent benefits for people with elevated homocysteine or seeking its osmolyte performance effects. These are valid reasons to take TMG. "NMN depletes your methyl groups" is not a valid reason based on current evidence.

Frequently Asked Questions

Do you need TMG with NMN?

No. The methyl depletion claim is based on nicotinamide (NAM) metabolism, not NMN. A 2026 human RCT in 65 adults found NMN at 1,000mg per day produced no homocysteine elevation, while nicotinamide at 500mg caused more than an eightfold increase. Standard NMN doses do not create the methyl demand that makes TMG necessary.

Why do some brands say you need TMG with NMN?

The argument applies a real mechanism (NAM methylation uses SAM) to the wrong molecule (NMN). Brands selling TMG as a companion to NMN have a commercial incentive to do so, and the mechanism sounds credible enough to generate concern. Human clinical data showing NMN does not elevate homocysteine directly contradicts the claim, but this data is less prominently referenced than the theoretical argument.

What is TMG and what does it actually do?

TMG (trimethylglycine, betaine anhydrous) is a natural methyl donor found in beets, spinach, and quinoa. It donates a methyl group to convert homocysteine back to methionine via the BHMT enzyme, supporting SAM regeneration. Clinical trials show it lowers elevated homocysteine and has osmolyte performance effects. These are valid independent reasons to take TMG, unrelated to any NMN-driven methyl depletion claim.

What is the methyl group depletion theory?

It is the hypothesis that NAD+ supplementation increases the production of nicotinamide (NAM) as a catabolism byproduct, and that clearing NAM via NNMT methylation depletes SAM, potentially impairing DNA methylation, neurotransmitter synthesis, and other methylation reactions. This mechanism is real for direct high-dose NAM supplementation. For NMN supplementation, human trial data shows the NAM produced downstream does not cause detectable SAM depletion at standard doses.

Could anyone need TMG with NMN?

Yes, in specific situations: very high NMN doses above 1g per day where more NAM catabolism occurs; MTHFR gene variants that reduce the folate-dependent remethylation pathway; pre-existing elevated homocysteine; or very low dietary methyl donor intake. For most people at standard 250-500mg NMN doses with a varied diet, TMG is not required.

Is NMN safe without TMG?

Yes. Every human clinical trial of NMN (including trials at 250, 300, 500, 600, 900, and 1,250mg per day for up to 12 weeks) has reported NMN was well-tolerated with no significant adverse laboratory findings including no methylation-related adverse effects. The Christen 2026 trial specifically confirmed no homocysteine elevation at 1,000mg per day NMN.

What is the difference between NMN and nicotinamide (NAM)?

NMN converts to NAD+ directly via NMNAT enzymes, bypassing the NAM-to-NMN NAMPT step. NAM is a simpler B3 form that must be converted to NMN by NAMPT first, and is also the primary substrate for NNMT-mediated methylation excretion. When you supplement NAM directly, you flood the methylation clearance pathway. When you supplement NMN, NAM only appears as a downstream catabolism product at physiologically regulated amounts, not at supplement-dose concentrations.